Drug-eluting device coating services market seen hitting $1.43 billion by 2030

The drug-eluting device coating services market is projected to grow from $1.04 billion in 2025 to $1.43 billion by 2030, driven by demand for localized drug delivery and advanced release profiles. North America leads now, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Drug-eluting device coatings help medical devices deliver therapy directly at the treatment site, which can improve outcomes and reduce systemic side effects. - The market’s growth points to rising demand for targeted therapies, especially in cardiovascular and other chronic disease treatments. - The forecast suggests more need for coating development, validation, and regulatory-compliant testing across the device supply chain.

What happened: - The Business Research Company published its Drug-Eluting Device Coating Services Global Market Report 2026, covering market size, trends, and forecasts for 2026-2035. - The market is projected to rise from $1.04 billion in 2025 to $1.1 billion in 2026. - The report forecasts the market will reach $1.43 billion by 2030, at a 6.6% CAGR. - The company said the report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The details: - Drug-eluting device coating services apply drug-containing or drug-releasing layers to medical devices. - The coatings are designed to provide controlled, localized delivery at the intended treatment site. - The services focus on consistent drug loading, uniform coatings, strong adhesion, stability, and reliable drug-release performance. - The market’s recent expansion has been driven by rising cardiovascular disease prevalence, greater adoption of drug-eluting medical devices, wider use of coated cardiovascular implants, and growing demand for localized therapeutic drug delivery. - The forecast period is expected to be supported by demand for advanced drug-release profiles, combination drug coatings, and expansion into new device applications. - Other expected trends include precise drug loading and release control, biocompatible coating materials, stronger coating adhesion, long-term stability, and regulatory-compliant validation and testing. - The report cites growing use of drug-coated balloons in coronary interventions as an example of adoption trends. - The Spanish Society of Cardiology reported that procedures using drug-coated balloons increased from 2,891 in 2022 to 3,852 in 2023, a 33.2% increase. - From 2021 to 2023, those procedures rose 92% cumulatively.

Between the lines: - The market outlook reflects a shift from simple coating application toward more technical services tied to performance, durability, and regulatory evidence. - The emphasis on combination coatings and personalized delivery suggests customers want more specialized products, not just broader coating capacity. - North America’s current lead likely reflects established adoption and infrastructure, while Asia-Pacific’s growth outlook points to room for broader procedural uptake and manufacturing activity.

What's next: - Demand will likely track adoption of drug-eluting devices in cardiovascular care and other localized therapy applications. - Coating providers may face more pressure to prove release control, adhesion, stability, and compliance through testing and validation. - The company’s report points to continued monitoring of regional growth, especially in Asia-Pacific, as the fastest-expanding market.